Viva Biotech
Viva Biotech Holdings is a Shanghai-based company that specializes in structure-based drug discovery services for biotechnology and pharmaceutical clients worldwide. Founded in 2008, the company offers a comprehensive range of research and development services, including fragment-based drug discovery and advanced screening technologies such as affinity selection mass spectrometry and cryo-electron microscopy. Viva Biotech provides various products, including cell lines, crystal structures, GPCR proteins, and antibodies, alongside services in medicinal chemistry, in vitro pharmacology, and antibody discovery. The company operates as an integrated drug discovery platform, combining its expertise in early-stage drug research with contract development and manufacturing services for small molecule active pharmaceutical ingredients and intermediates. Its innovative approach and advanced technological platforms position Viva Biotech as a valuable partner in the global drug development landscape.
7 past transactions
Eubulus
Series A in 2021
Eubulus is an early-stage company focusing on building a platform technology for therapeutic enhancement. The company specializes in Proteolysis- targeting chimeras (PROTACSs).
Totient
Seed Round in 2020
Totient Inc. is an AI-driven biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in using advanced machine learning and immunoinformatics to analyze complex datasets in the field of drug discovery and development. It focuses on identifying novel tissue-specific antigens and reconstructing high-affinity antibody therapeutics from tissues impacted by cancer, autoimmune diseases, and infections. By leveraging its platform's unique capabilities, Totient aims to quickly and accurately identify potent antibody candidates suitable for a variety of therapeutic applications, including cell therapies and bispecific antibodies. This innovative approach positions the company to address significant medical challenges in multiple areas of healthcare.
Triumvira Immunologics
Series A in 2020
Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.
Regenacy Pharmaceuticals
Series A in 2020
Regenacy Pharmaceuticals, LLC is a biopharmaceutical company founded in 2016 and located in Boston, Massachusetts. The company specializes in developing treatments for peripheral neuropathies, hemoglobinopathies, and specific oncology indications. Its innovative approach focuses on regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy's lead product, ricolinostat, serves as a selective HDAC6 inhibitor, which enables the treatment of conditions such as sickle cell disease and beta-thalassemia. Through its targeted therapeutic strategies, Regenacy aims to address significant unmet medical needs in various disease areas.
DTx Pharma
Series A in 2020
DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.
AcuraStem
Convertible Note in 2019
AcuraStem is a biotechnology company based in Monrovia, California, founded in 2016. The company specializes in developing a precision medicine platform that utilizes complex cellular models derived from Amyotrophic Lateral Sclerosis (ALS) patients' cells. AcuraStem employs advanced cellular reprogramming and artificial intelligence technologies to create patient-specific treatments for neurodegenerative diseases. Their platform is designed to evaluate disease progression and test existing therapeutics, as well as combinations of therapeutic approaches, to identify effective treatments that could slow disease progression. The company's team includes PhDs, professors, tech entrepreneurs, and veterans from the drug industry, all working towards addressing the challenges posed by ALS.
Mebias Discovery
Venture Round in 2019
Mebias Discovery, LLC is a pharmaceutical company focused on the discovery and development of pathway-selective drugs targeting G-protein coupled receptors (GPCRs). Founded in 2015 and headquartered in Philadelphia, Pennsylvania, the company aims to identify innovative molecules that bind to GPCRs, thereby minimizing on-target side effects traditionally associated with drug therapies. Mebias Discovery's technology emphasizes validated drug discovery methods, offering a robust platform that reduces the risks typically associated with exploring new therapeutic mechanisms. The company's research primarily targets neurodegenerative disorders, mood disorders, non-opioid pain management, cardiovascular conditions, and immuno-oncology, presenting significant opportunities for healthcare providers to address various diseases with improved therapeutic profiles.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.